Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction

Blood

Volumn 95, Issue 2, 2000, Pages 569-576

  Kunz, Gabriella ^a,c   Ireland, Helen A ^b   Stubbs, Peter J ^a   Kahan, Mel ^a   Coulton, Gary C ^b   Lane, David A ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; THROMBIN; THROMBOMODULIN;

ADULT; ALLELE; ANIMAL CELL; ARTICLE; CASE REPORT; CELLULAR DISTRIBUTION; ENDOTHELIUM CELL; FRAMESHIFT MUTATION; GENE MUTATION; GENE SEQUENCE; HEART INFARCTION; HUMAN; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSLATION;

EID: 0034650999     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.2.569     Document Type: Article

References (41)

1. Esmon CT. Defects in natural anticoagulant pathways as potential risk factors for myocardial infarction. Circulation. 1997;96:9-11.
2. McNamara CA, Sarembock U, Gimple LW, Fenton JWD, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993:91:94-98.
3. Chen LB, Buchanan JM. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sei U S A. 1975;72:131 -135.
4. Zimmerman GA, Mclntyre TM, Prescott SM. Thrombin stimulates neutrophil adherence by an endothelial cell-dependent mechanism: characterization of the response and relationship to platelet-activating factor synthesis. Ann N Y Acad Sei. 1986:485:349-368.
5. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991:30:10,363-10,370.
6. Esmon CT. The regulation of natural anticoagulant pathways. Science. 1987;235:1348-1352.
7. Esmon CT, Owen WG. Identification of an endo-ihelial cell cofactor lor thrombin-catalyzed activation of protein C. Proc Nail Acad Sei U S A. 1981 ; 78:2249-2252.
8. Suzuki K, Nishioka J, Hayashi T, Kosaka Y. Functionally active thrombomodulin is present in human platelets. J Biochem Tokyo. 19B8;104:628-632.
9. McCachren SS. Diggs J, Weinberg JB, Dittman WA. Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood. 1991:78:3128-3132.
10. Mizutani H, Ohyanagi S, Hayashi T, Groves RW, Suzuki K, Shimizu M. Functional thrombomodulin expression on epithelial skin tumours as a differentiation marker for suprabasal keratinocytes. Br J Dermatol. 1996:135:187-193.
11. Wen DZ, Dittman WA, Ye RD, Deaven LL, Majerus PW, Sadler JE. Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene. Biochemistry. 1987;26: 4350-4357.
12. Sadler JE, Thrombomodulin structure and function. Thromb Haemost. 1997;78:392-395.
13. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 1995:9:946-955.
14. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 1. Thromb Haemost. 1996:76:651-662.
15. Poor! SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996:88:3698-3703.
16. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation. 1998:97:1037-1041.
17. Rosendaal FR, Siscovick DS, Schwanz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997:89:2817-2821.
18. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747-1750.
19. Ohlin AK, Nortund L, Martar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost. 1997;78:396-400.
20. Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations associated with myocardial infarction. Circulation. 1997;96:15-18.
21. Doggen CJ, Kunz G, Rosendaal FR. et al. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction. Thromb Haemost. 1998:80:743-748.
22. Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem. 1992:267:6164-6170.
23. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985:230:1350-1354.
24. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DMA. Mol Cell Biol. 1987:7:2745-2752.
25. Suzuki K, Kusumoto H, Deyashiki Y, et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J. 1987:6: 1891-1897.
26. Boisclair MD, Une DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISAfor prothrombin fragment F1 + 2. Thromb Haemost. 1993;70:253-258.
27. Lewin B. Protein trafficking. In: Genes. VI (ed VI). . New York: Oxford University Press; 1997:10271051.
28. Boisclair MD, Philippou H, Lane DA. Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers. Blood Coagul Fibrinolysis. 1993; 4:1007-1021.
29. Mannucci PM, Tripodi A, Bottasso B, et al. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost. 1992:67:200-202.
30. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555-1564.
31. Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet. 1999;353:1729-1734.
32. Le Hem L, Picard V, Emmerich J, et al. Mutations in promoter region of thrombomodulin and venous thromboembolic disease. Arterioscler Thromb Vase Biol. 1999:19:1098-1104.
33. Norlund L, Zoller B, Ohlin AK. A novel thrombo-modulin gene mutation in a patient suffering from sagittal sinus thrombosis. Thromb Haemost. 1997:78:1164-1166.
34. van der Velden PA, Krommenhoek Van Es T, AllaartCF, Bertina RM, Reitsma PH. A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia. Thromb Haemost. 1991;65:511-513.
35. Noriund L, Holm J, Zoller B, Ohlin AK. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost. 1997;77:248-251.
36. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophiiia: part 2. Thromb Haemost. 1996:76:824-834.
37. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell. 1993:72:477-480.
38. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. 1987;317:991-996.
39. Rosenberg RD. Thrombomodulin gene disruption and mutation in mice. Thromb Haemost. 1997;78: 705-709.
40. Weiler Guettier H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest. 1998:101:1983-1991.
41. Hanson SR, Griffin JH, HarkerLA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest. 1993:92:20032012.